Clinical trials: Polycystic Kidney Diseases
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Study of Tamibarotene in Patients With ADPKD
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
- Trial name
- NCT06289998
- Testing
- Tamibarotene
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Rege Nephro Co., Ltd.
Chronic Renal Failure, Polycystic Kidney Disease
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02166489
- Testing
- Intravenous injection autologous mesenchymal stem cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE.
- Trial name
- NCT07074327
- Testing
- VX-407, LNG/EE, NGM/EE
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
New Phenotype (Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia)
Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia
This study involves a single family, including 1 patient, father, mother and sister. The patient presented with a new phenotype associating premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia.
- Trial name
- BCL-2 (NCT03651388)
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
- Trial name
- AGLOW (NCT07161037)
- Testing
- VX-407
- Where
- 43 sites in United States, Belgium and 6 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Polycystic Kidney, Autosomal Dominant, Chronic Kidney Diseases
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct.
- Trial name
- POVA (NCT04363554)
- Testing
- Fluid intake, Thirsting
- Where
- Denmark
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Autosomal Dominant Polycystic Kidney Disease
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).
- Trial name
- NCT00841568
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Polycystic Kidney, Autosomal Dominant, ADPKD
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
This study evaluates the effect of regulating salt and protein intake on urinevolume in patients with ADPKD treated with a vasopressine V2 receptor antagonist (V2RA).
- Conditions
- Polycystic Kidney, Autosomal Dominant, ADPKD, Autosomal Dominant Polycystic Kidney
- Trial name
- WATER (NCT04310319)
- Testing
- Sodiumchloride, Protein
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Esther Meijer
Polycystic Kidney Disease
Early PKD Observational Cohort Study
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also…
- Trial name
- EPOC (NCT02936791)
- Where
- 3 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
- Trial name
- NCT07868926
- Testing
- 14C-VX-407
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.
- Trial name
- NCT00598377
- Testing
- Tetracosactin
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal…
- Trial name
- PENGUIN (NCT04407481)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Colorado, Denver
Polycystic Kidney, Autosomal Dominant
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal…
- Trial name
- STAGED-PKD (NCT03523728)
- Testing
- Venglustat
- Where
- 95 sites in United States, Argentina and 21 more
- Volunteers
- 478 people
- Sponsor
- Genzyme, a Sanofi Company
Autosomal Dominant Polycystic Kidney Disease
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
This is an one-year open-label study to determine treatment efficacy and feasibility of a trial that uses open-label interventions in ADPKD patients.
- Trial name
- ADPKD-SAT (NCT04284657)
- Testing
- Pravastatin, sodium citrate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Southern California
Polycystic Kidney Diseases
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocking capabilities (4), namely…
- Trial name
- NCT00286156
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Autosomal Dominant Polycystic Kidney, Renal Cyst
A Prospective Observational Study of Foam Sclerotherapy .
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with…
- Conditions
- Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
- Trial name
- NCT04111692
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease
Effects of Somatostatin on Liver in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a variety of extrarenal manifestations of which polycystic liver disease is most common.
- Trial name
- NCT02119052
- Testing
- octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
The primary aim of this observational exploratory study is to develop AI-based image processing methods to advance the characterization of Polycystic Kidney Disease using medical images and associated clinical data, including: 1.
- Trial name
- AI4PKD (NCT06688981)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney Diseases
Everolimus on CKD Progression in ADPKD Patients
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
- Trial name
- NCT01009957
- Testing
- Everolimus
- Where
- 7 sites in Italy
- Volunteers
- 71 people
- Sponsor
- A. Manzoni Hospital